End-stage diastolic and systolic heart failure: Evaluation and timing of heart transplantation

Eric D. Popjes, Anjali Tiku Owens, Anjali Tiku Owens, Anjali Tiku Owens

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

End stage hypertrophic cardiomyopathy occurs in an estimated 3-15 % of patients and can present as either systolic or diastolic dysfunction. Risk factors for developing end stage disease include a family history of end stage disease, younger age at initial diagnosis, increased wall thickness and persistent arrhythmia. The classic form of adverse remodeling includes left ventricular cavity dilation with regression of hypertrophy and decrease in ejection fraction. Standard medical therapy for systolic heart failure and consideration of prophylactic defibrillator is indicated when LVEF is less than 50 %. Heart transplant is a viable option for patients with end stage hypertrophic cardiomyopathy, including those with systolic heart failure, diastolic heart failure or refractory arrhythmia. Strategies used to bridge patients to transplant include continuous inotropic infusion, left ventricular assist device, intra-aortic balloon pump, and in rare cases extracorporeal membrane oxygenation. Survival after heart transplant for hypertrophic cardiomyopathy is equal to or better than survival for patients who have other types of cardiomyopathies.

Original languageEnglish (US)
Title of host publicationHypertrophic Cardiomyopathy
Subtitle of host publicationForeword by Bernard Gersh and Historical Context by Eugene Braunwald
PublisherSpringer-Verlag London Ltd
Pages247-254
Number of pages8
ISBN (Electronic)9781447149569
ISBN (Print)9781447149552
DOIs
StatePublished - Jan 1 2015

Fingerprint

Diastolic Heart Failure
Systolic Heart Failure
Heart Transplantation
Hypertrophic Cardiomyopathy
Transplants
Cardiac Arrhythmias
Extracorporeal Membrane Oxygenation
Ventricular Remodeling
Heart-Assist Devices
Defibrillators
Survival
Cardiomyopathies
Hypertrophy
Dilatation

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Popjes, E. D., Owens, A. T., Owens, A. T., & Owens, A. T. (2015). End-stage diastolic and systolic heart failure: Evaluation and timing of heart transplantation. In Hypertrophic Cardiomyopathy: Foreword by Bernard Gersh and Historical Context by Eugene Braunwald (pp. 247-254). Springer-Verlag London Ltd. https://doi.org/10.1007/978-1-4471-4956-9_20
Popjes, Eric D. ; Owens, Anjali Tiku ; Owens, Anjali Tiku ; Owens, Anjali Tiku. / End-stage diastolic and systolic heart failure : Evaluation and timing of heart transplantation. Hypertrophic Cardiomyopathy: Foreword by Bernard Gersh and Historical Context by Eugene Braunwald. Springer-Verlag London Ltd, 2015. pp. 247-254
@inbook{86f03f535d414db589d60a5e233b3f9d,
title = "End-stage diastolic and systolic heart failure: Evaluation and timing of heart transplantation",
abstract = "End stage hypertrophic cardiomyopathy occurs in an estimated 3-15 {\%} of patients and can present as either systolic or diastolic dysfunction. Risk factors for developing end stage disease include a family history of end stage disease, younger age at initial diagnosis, increased wall thickness and persistent arrhythmia. The classic form of adverse remodeling includes left ventricular cavity dilation with regression of hypertrophy and decrease in ejection fraction. Standard medical therapy for systolic heart failure and consideration of prophylactic defibrillator is indicated when LVEF is less than 50 {\%}. Heart transplant is a viable option for patients with end stage hypertrophic cardiomyopathy, including those with systolic heart failure, diastolic heart failure or refractory arrhythmia. Strategies used to bridge patients to transplant include continuous inotropic infusion, left ventricular assist device, intra-aortic balloon pump, and in rare cases extracorporeal membrane oxygenation. Survival after heart transplant for hypertrophic cardiomyopathy is equal to or better than survival for patients who have other types of cardiomyopathies.",
author = "Popjes, {Eric D.} and Owens, {Anjali Tiku} and Owens, {Anjali Tiku} and Owens, {Anjali Tiku}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-1-4471-4956-9_20",
language = "English (US)",
isbn = "9781447149552",
pages = "247--254",
booktitle = "Hypertrophic Cardiomyopathy",
publisher = "Springer-Verlag London Ltd",

}

Popjes, ED, Owens, AT, Owens, AT & Owens, AT 2015, End-stage diastolic and systolic heart failure: Evaluation and timing of heart transplantation. in Hypertrophic Cardiomyopathy: Foreword by Bernard Gersh and Historical Context by Eugene Braunwald. Springer-Verlag London Ltd, pp. 247-254. https://doi.org/10.1007/978-1-4471-4956-9_20

End-stage diastolic and systolic heart failure : Evaluation and timing of heart transplantation. / Popjes, Eric D.; Owens, Anjali Tiku; Owens, Anjali Tiku; Owens, Anjali Tiku.

Hypertrophic Cardiomyopathy: Foreword by Bernard Gersh and Historical Context by Eugene Braunwald. Springer-Verlag London Ltd, 2015. p. 247-254.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - End-stage diastolic and systolic heart failure

T2 - Evaluation and timing of heart transplantation

AU - Popjes, Eric D.

AU - Owens, Anjali Tiku

AU - Owens, Anjali Tiku

AU - Owens, Anjali Tiku

PY - 2015/1/1

Y1 - 2015/1/1

N2 - End stage hypertrophic cardiomyopathy occurs in an estimated 3-15 % of patients and can present as either systolic or diastolic dysfunction. Risk factors for developing end stage disease include a family history of end stage disease, younger age at initial diagnosis, increased wall thickness and persistent arrhythmia. The classic form of adverse remodeling includes left ventricular cavity dilation with regression of hypertrophy and decrease in ejection fraction. Standard medical therapy for systolic heart failure and consideration of prophylactic defibrillator is indicated when LVEF is less than 50 %. Heart transplant is a viable option for patients with end stage hypertrophic cardiomyopathy, including those with systolic heart failure, diastolic heart failure or refractory arrhythmia. Strategies used to bridge patients to transplant include continuous inotropic infusion, left ventricular assist device, intra-aortic balloon pump, and in rare cases extracorporeal membrane oxygenation. Survival after heart transplant for hypertrophic cardiomyopathy is equal to or better than survival for patients who have other types of cardiomyopathies.

AB - End stage hypertrophic cardiomyopathy occurs in an estimated 3-15 % of patients and can present as either systolic or diastolic dysfunction. Risk factors for developing end stage disease include a family history of end stage disease, younger age at initial diagnosis, increased wall thickness and persistent arrhythmia. The classic form of adverse remodeling includes left ventricular cavity dilation with regression of hypertrophy and decrease in ejection fraction. Standard medical therapy for systolic heart failure and consideration of prophylactic defibrillator is indicated when LVEF is less than 50 %. Heart transplant is a viable option for patients with end stage hypertrophic cardiomyopathy, including those with systolic heart failure, diastolic heart failure or refractory arrhythmia. Strategies used to bridge patients to transplant include continuous inotropic infusion, left ventricular assist device, intra-aortic balloon pump, and in rare cases extracorporeal membrane oxygenation. Survival after heart transplant for hypertrophic cardiomyopathy is equal to or better than survival for patients who have other types of cardiomyopathies.

UR - http://www.scopus.com/inward/record.url?scp=84948105290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948105290&partnerID=8YFLogxK

U2 - 10.1007/978-1-4471-4956-9_20

DO - 10.1007/978-1-4471-4956-9_20

M3 - Chapter

AN - SCOPUS:84948105290

SN - 9781447149552

SP - 247

EP - 254

BT - Hypertrophic Cardiomyopathy

PB - Springer-Verlag London Ltd

ER -

Popjes ED, Owens AT, Owens AT, Owens AT. End-stage diastolic and systolic heart failure: Evaluation and timing of heart transplantation. In Hypertrophic Cardiomyopathy: Foreword by Bernard Gersh and Historical Context by Eugene Braunwald. Springer-Verlag London Ltd. 2015. p. 247-254 https://doi.org/10.1007/978-1-4471-4956-9_20